Is Repligen (RGEN) Still Undervalued Following Its $1.5b BioLife Deal?Simplywall·Jul 23 at 08:19 AMRGEN-4.10%BLFS-2.57%
Biotech Stocks At 52-Week Highs - ADVB Surges +73%, BLFS Rises After Acquisition, FBRX, SLN, LBRXrttnews·Jul 23 at 03:38 AMSLN-3.76%FBRX-8.24%
BioLife Solutions to Be Acquired by Repligen for $11.25 Cash Plus 0.1442 Share Per ShareTradingView·Jul 22 at 04:23 PMBLFS-2.57%RGEN-4.10%
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media | RGEN Stock NewsStockTitan·Jul 21 at 09:00 PMBLFS-2.57%RGEN-4.10%
11:34 ETShareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholdersprnewswire·Jul 22 at 10:35 AMBLFS-2.57%RGEN-4.10%
Hold Rating Maintained as Repligen Acquisition Caps BioLife Upside; Price Target Cut to $31 from $33Tip Ranks·Jul 22 at 09:45 AMBLFS-2.57%RGEN-4.10%
Repligen to buy BioLife Solutions for about USD 1.5 billion, offers USD 31 a sharePUBT·Jul 22 at 05:02 AMBLFS-2.57%RGEN-4.10%
